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LETTER TO THE EDITOR
Letter by van der Ende et al Regarding Article, “Redefined Measure of Early 
Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo”
Nadinda A.M. van der Ende , MD; Vicky Chalos, MD; Diederik W.J. Dippel, MD, PhD
To the Editor:
With great interest we read the article by Agarwal et 
al,1 who proposed a redefined measure of early neuro-
logical improvement (ENI). This ENI, defined as percent-
age change in National Institutes of Health Stroke Scale 
(NIHSS) from baseline to 24 hours, showed treatment 
benefit of alteplase in the NINDS trial. This is an impor-
tant finding. However, we have some comments.
The authors propose that ENI is a reliable and sensi-
tive measure of treatment effect in trials of acute reper-
fusion therapy for ischemic stroke. There are several 
limitations to the approach of the authors that preclude 
such a conclusion. First, the authors used descrip-
tive statistics to assess treatment benefit of alteplase, 
which—in contrast to regression models—do not allow for 
adjustment of prognostic covariates. In general, includ-
ing baseline linear variables as covariate in a regression 
analysis is more efficient than using percentage change.2 
Regression models have the additional advantage that 
they accommodate covariate adjustment to increase sta-
tistical power considerably.3 Second, it is unclear what 
NIHSS score was assigned to patients who died within 
the 24-hour period after inclusion in the trial. This may 
affect the size and interpretation of the effect param-
eter “percent change.” Third, a strong predictive ability for 
3-month outcome, and one statistically significant effect 
by itself does not ensure that ENI is a valid surrogate 
marker of treatment effect. A surrogate outcome should 
be able to replace the true outcome as a measure of 
treatment effect, and should lie in the causal pathway 
between the intervention and true outcome.4 Statistical 
validation of these criteria require assessment with a 
causal mediation model, even when intuition may sug-
gest that these criteria will be satisfied anyway.
We argue that a more extensive study, which takes all 
these issues into account, is needed. We are very happy 
to point out to the authors that such a study has already 
been done, and has recently been published in Stroke.5 
Using data of two trials of endovascular treatment, that 
study showed that the NIHSS at 24 hours satisfies the 
requirements for a surrogate outcome. Patients who had 
died before posttreatment NIHSS assessment received 
the maximum score of 42, which led to a non-normal 
distribution, requiring log10-transformation.
As mentioned by the authors, the definition of ENI 
varies across studies. The most statistically efficient defi-
nition and method of analyzing ENI is currently unknown 
and a comparison of these definitions and methods is 
necessary.
In conclusion, we thank the authors for drawing our 
attention to the use of NIHSS as a sensitive early mea-
sure of treatment effect in trials of acute reperfusion 
therapy for ischemic stroke. It is important to decide 
which types of studies benefit most of this early outcome 
measure and how it should be analyzed. We already 
knew that linear regression with covariate adjustment 
increases statistical power, but the most efficient defini-
tion and method of analyzing ENI is not yet known and 
needs to be studied further.
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